Cortexin vs P21 (CNTF-Derived Peptide)
Research Verdict
Cortexin is the stronger research reference for the stated comparison criteria. Cortexin: approved in Russia, Russian clinical data for neuroprotection.
Quick Answers
Which is better, Cortexin or P21 (CNTF-Derived Peptide)?
Cortexin is the stronger research reference for the stated comparison criteria. Cortexin: approved in Russia, Russian clinical data for neuroprotection.
What is the key difference between Cortexin and P21 (CNTF-Derived Peptide)?
Cortexin is a bovine brain-derived mixture with decades of Russian clinical use; P21 is a defined synthetic peptide fragment - the tradeoff is clinical experience vs. molecular precision.
Evidence Comparison
Cortexin: approved in Russia, Russian clinical data for neuroprotection. P21 peptide: preclinical rodent neurogenesis studies only, no human data. Cortexin has the clinical use advantage, though its evidence quality is limited by lack of independent validation.
Evidence Context Favoring Cortexin
Contexts where Russian regulatory approval and clinical usage history are considered relevant evidence.
Evidence Context Favoring P21 (CNTF-Derived Peptide)
Mechanistic neurogenesis research requiring a defined synthetic peptide with a known molecular target.
Side-by-Side Snapshot
| Evidence grade | Cortexin: Level C P21 (CNTF-Derived Peptide): Level D |
|---|---|
| Research status | Cortexin: Approved Outside US P21 (CNTF-Derived Peptide): Preclinical |
| Primary category | Cortexin: Cognitive & Nootropic P21 (CNTF-Derived Peptide): Cognitive & Nootropic |
| Cited studies | Cortexin: 2 P21 (CNTF-Derived Peptide): 2 |